CI

At a glance

ClinicalIndex Comparison Record
N/ANot Yet Recruiting· 912 target
Drug / intervention
Methylprednisolone sodium succinate +1 moredrug
Likely dose
Methylprednisolone sodium succinate 2 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07175649
NCT07175649N/ANot Yet Recruiting

Methylprednisolone Sodium Succinate With Endovascular ThRombectomy for Large Ischemic STroke: A Randomized, Double-blind, Placebo-controlled Trial

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University·interventional·Posted Sep 16, 2025·Updated Sep 16, 2025

In Brief

A clinical study evaluating Methylprednisolone sodium succinate and Placebo for Ischemic Stroke, Acute. Not yet recruiting, targeting 912 participants across 1 site.

Detailed Summary

It is uncertain whether intravenous methylprednisolone improves outcomes for acute anterior circulation large vessel occlusion (LVO) patients with a large infarct core. In this study, the investigators hypothesize that methylprednisolone plus endovascular thrombectomy (EVT) might be superior to EVT alone in patients with evidence of a large infarct volume. The primary objective of the study is to establish the efficacy of methylprednisolone with EVT in patients with acute anterior circulation LVO and a large infarct core.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--

Timeline

N/ANot Yet Recruiting
20262027202820292030
First PostedSep 16, 2025
Enrollment StartOct 1, 2025
Primary CompletionDec 1, 2028
Study CompletionDec 1, 2029
TodayJul 1, 2026
Enrollment to primary: 3.2 yearsPosted 10 months agoPrimary completion in 2.4 years

Interventions

Methylprednisolone sodium succinatedrug

Intravenous methylprednisolone sodium succinate will be administered at a dose of 2 mg/kg/day for 3 days, with a maximum daily dose of 160 mg (4 vials, 40 mg/vial). It is recommended that the initial dose be administered as soon as possible after randomization.

Placebodrug

Matched intravenous placebo will be administered for 3 days, with a maximum daily dose of 4 vials.